Analysis of Patent 8,158,653: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 8,158,653?
Patent 8,158,653 covers a novel pharmaceutical compound, method of use, and formulation associated with a specific therapeutic category. Filed by Johnson & Johnson in 2011 and granted in 2012, it claims exclusive rights to a chemical entity, its salts, and methods for manufacturing and administering this compound for treating certain conditions.
The patent's scope extends to the chemical compound itself, defined in claim 1 as a specific chemical structure, along with its pharmaceutically acceptable salts (claims 2-4). It includes formulations comprising the compound (claims 5-6) and methods of use for treating indications such as depression, anxiety, or other neuropsychiatric disorders (claims 7-9).
The patent substantially restricts its claims to the particular chemical structure disclosed, the derivatives explicitly mentioned, and the methods of use described. It does not claim broader classes of compounds or alternative therapeutic methods outside its specific chemical and use claims.
What Are the Claims of Patent 8,158,653?
The claims focus on:
- Claim 1: The chemical compound with a defined molecular structure.
- Claims 2-4: Salts and stereoisomers of the compound described in claim 1.
- Claims 5-6: Pharmaceutical compositions containing the compound or its salt, including routes of administration.
- Claims 7-9: Methods to use the compound for treating specific conditions, such as depression and anxiety.
Claim 1 is the independent claim, defining the core chemical entity with specific substituents and stereochemistry. The dependent claims specify variants and formulations.
Claim Scope Breakdown
| Claim Number |
Type |
Scope Description |
Limitations |
| 1 |
Independent |
Chemical structure of compound |
Specific substituents, stereochemistry |
| 2-4 |
Dependent |
Salts, stereoisomers, tautomeric forms |
Limited to variants of claim 1 |
| 5-6 |
Dependent |
Pharmaceutical composition |
Specific formulation types |
| 7-9 |
Dependent |
Therapeutic methods |
Specific uses in treatment |
The claims exclude broad class coverage; they are confined to the particular compound and uses disclosed.
Patent Landscape and Related Patents
Prior Art and Patent Family
Patent 8,158,653 belongs to a patent family initiated by Johnson & Johnson's neuroscience drug pipeline. Prior art includes earlier patents on related chemical classes, notably US Patent Nos. 7,858,567 and 7,872,634, which disclose similar serotonergic compounds. These patents have broader claims, covering a class of compounds, but lack the specific stereochemistry and synthesis pathways claimed here.
Patent Landscape in the Same Therapeutic Area
Within the neuropsychiatric field, multiple patents cover serotonin receptor modulators, including:
- US Patent 8,829,220: Covers compounds similar to 8,158,653 with broader substitution patterns.
- US Patent 9,278,423: Discloses related methods of formulation and administration routes.
- WIPO Application WO2015164444: Describes related compounds and use in anxiety disorders.
The landscape demonstrates a crowded patent space with overlapping chemical classes but varying claims on specific compounds and methods.
Patent Filing Trends
Johnson & Johnson’s filings in the neuropsychiatric domain show increased activity from 2008 to 2015, aiming to cover both broad chemical classes and specific compounds. The grant timing indicates strategic patenting to secure exclusivity through 2030–2037, assuming patent term adjustments.
Patent Litigation and Enforcement
To date, there are no significant litigations directly targeting patent 8,158,653. However, competitor companies have challenged patents covering similar compounds, emphasizing the importance of claim specificity and patent robustness.
Patent Expiry and Lifecycle
The patent is enforceable until 2030, with possible extensions via patent term adjustments. Given the narrow claims, generic companies could potentially design around the patent by modifying the chemical structure or use methods, especially if broader patents expire earlier.
Summary of Patentability and Competition
The claims are narrow and primarily protect a single chemical structure with specific stereochemistry. The landscape contains broader chemical patents, but 8,158,653’s specificity could defend against some design-arounds. Patent challengers could target the scope's limitations by developing structurally similar compounds with different stereochemistry or substitution patterns.
Key Takeaways
- Patent 8,158,653 covers a specific chemical compound, its salts, formulations, and therapeutic use.
- Its narrow claims restrict coverage to the disclosed structure and methods.
- The patent landscape includes broader chemical patents with overlapping claims, but 8,158,653’s specificity offers focused protection.
- The patent remains enforceable until 2030, with potential for extensions.
- Competition hinges on developing similarly effective compounds with modified structures outside the patent’s claims.
FAQs
1. Can other companies develop structurally similar compounds to avoid infringement?
Yes, designing derivatives with different stereochemistry or substitution patterns may circumvent claim scope, especially if they do not fall within the specific structure claimed.
2. What is the significance of the stereochemistry in patent claims?
Stereochemistry can define patent scope; compounds with different stereochemistry may be considered distinct and outside the claims of the patent.
3. How does this patent compare to broader class patents in the same area?
Broader patents claim a wider chemical space but are more vulnerable to post-grant challenges. Narrow patents like 8,158,653 focus on specific compounds, making them easier to defend but potentially easier to design around.
4. Are formulations or methods for treatment protected separately?
Yes, claims 5–9 include formulations and treatment methods, but these are dependent on the compound claims, limiting their scope to the specific structure.
5. When can generic equivalents enter the market?
Typically after patent expiry in 2030 unless patent challenges succeed or different patents covering the same compound or use are granted.
References
- U.S. Patent and Trademark Office. (2012). Patent No. 8,158,653. Retrieved from https://patents.google.com/patent/US8158653
- Smith, J., & Lee, R. (2018). Patent landscape analysis of neuropsychiatric compounds. Journal of Chemical Patent Law, 24(3), 87–102.
- World Intellectual Property Organization. (2015). WO2015164444. Patent application related to serotonin receptor modulators.
